Phaseline

Targets › GABRA

GABRA: drug programs, companies and trials

1 program from 1 company in 5 trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Neurology, Psychiatry; next expected readout Jun 2027.

Open in Phaseline: the race on GABRA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rapport TherapeuticsRAP-219
GABA-A positive allosteric modulator
GABRAPhase 3Focal Seizure; Bipolar 1 Disorder; Focal Epilepsy; EpilepsyJun 2027

Conditions

Focal Seizure (2) Bipolar 1 Disorder (1) Focal Epilepsy (1) Epilepsy (1)

Modalities

small molecule (1)

Companies

Rapport Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.